Exploring the role of cancer stemness and stromal interactions in therapeutic targeting of oncofetal chondroitin sulfate glycosaminoglycans in cancer ****************************************************************************************** * ****************************************************************************************** Number: MA/25/F1/0/018 Flagship: 1 - Urban Health and Demographic Change Faculty: LFP Project leader: Hatina, Jiří The rising incidence of major cancer types in the ageing population calls for new therapeu Targeting cancer stem cells is a promising approach, and the project brings together compl expertise to address this challenge. The Pilsen group has developed reporter cell strains visualization of bladder cancer stem cells, the Copenhagen group has created an innovative strategy, and the Warsaw group provides unique expertise in Grainy-Head-Like transcription which are key mediators of urothelial differentiation. The project builds on the Copenhagen group’s discovery that oncofetal chondroitin sulfate secondary modification otherwise present only in the placenta, reappears in all malignanci promotes rapid growth, invasion and immune escape. This finding led to the development of therapies, including a monoclonal antibody binding ofCS in cancer without affecting normal current research focuses on whether cancer stem cells express ofCS and how the cancer stro positive, using established biological models and new systems developed through manipulati induce or inhibit urothelial differentiation. The study will map the distribution of ofCS-modified antigens in bladder cancer stem cell cultures with stromal cells, and test therapeutic targeting of ofCS-expressing cells with conjugates. Improved cellular models will then undergo reanalysis to refine therapeutic st project is expected to result in a joint scientific publication or international conferenc while also strengthening long-term collaboration and mobility between participating groups University, the University of Copenhagen and the University of Warsaw, paving the way for funding applications.